ArticleSignal transduction and targeted therapy2025

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study.

Fei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.